Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authori...(and contact areas such as door handles h...),Health

Date:11/13/2007

and contact areas such as door handles, hand rails, fare card machine buttons, etc., in the event of a pandemic flu or other infectious disease outbreak Metro is prepared to use EnviroTru(TM) with the Foster-Miller, Inc. Electrostatic Charged Aerosol Decontamination System (ECADS) (http://www.fostermiller.com/ecadsproduct.htm) to spray rail cars, buses and other vehicles daily. ESI worked with Foster-Miller, Inc. to validate the use of its disinfectant with ECADS.

According to Foster-Miller, Inc. representative, Rick Lusignea, "Metro purchased 17 high efficiency air assisted ECADS sprayers from Foster-Miller to dispense EnviroTru(TM)". Mr. Lusignea explained, "The ECAD decontamination and remediation system disperses fine electrically charged droplets of decontaminant into the air. Because of the static charge imparted to aerosol particles, ECADS provides a much higher amount of disinfectant on surfaces than conventional air assisted spray systems, approximately 60% of the total disinfectant dispensed on the surface for the ECADS sprayer, versus less than 15% for conventional sprayers. We think the combination of our ECADS devices and the ESI disinfectant formulation is an extremely strong weapon against disease for Metro."

About Anpath Group, Incorporated:

Anpath Group, Inc., through its wholly-owned subsidiary EnviroSystems, Inc., produces cleaning and disinfecting products that it believes will help prevent the spread of infectious microorganisms while minimizing the harmful effects to people, equipment or the environment.

EnviroSystems, Inc. is focused on safe infection prevention technologies that the company believes will position the company in the forefront of the industry at a time when there is rapidly growing awareness of the critical need to prevent biological risks - both natural and man-made.

Forward Looking Statements:

This release contains for
'/>"/>

SOURCE Anpath Group, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study